Join our smart investors - Get the best stock directories in  blockchain, cannabis, crypto, AI, IoT, cleantech. Daily podcasts in cannabis and crpto. Just $99  a year

Frost & Sullivan Releases 10 Growth Opportunities in Precision Medical Imaging

Medical imaging’s critical role in supporting high impact patient care approaches centered on outcomes

 

Santa Clara, Calif. - February 7, 2019 (Investorideas.com Newswire) The triple aim objectives in healthcare provision and the focus on outcomes have driven interest in precision medicine paradigms across the board in the healthcare industry. The potential impact of personalization in diagnostic and therapeutic imaging on patient care approaches has resulted in the expansion of technologies and processes that will see the precision medical imaging market grow from $120 million in 2017 to over $8 billion by 2027. As healthcare becomes more patient-centric, technology advances such as clinical decision support software, sensors, 3D printing, and precision analytics capabilities like deep learning and artificial intelligence (AI) will be applied to medical imaging.

"Precision medical imaging has tremendous potential to improve all aspects of the care continuum, thus supporting emerging care approaches that are more targeted, predictive, translational, personalized and effective,” said Siddharth Saha, Vice President of Research, Transformational Health. "AI-enriched imaging equipment will help adapt and personalize the imaging protocols and procedures while precise radiomic and phenomic datasets from the given clinical context will enable deep learning, thereby reinforcing medical imaging's contribution to precision medicine. There are several firms in the ecosystem making very valuable contributions to the care pathways and this pool is set to exponentially grow in the short term."

Frost & Sullivan’s recent analysis, Growth Opportunities in Precision Medical Imaging, Forecast to 2022, defines the role of medical imaging in the precision medicine paradigm and assesses market opportunities. The growth opportunities are then mapped to the stages of the imaging care continuum-study ordering, image acquisition, image interpretation, image-based intervention, therapeutic dose radiation, and study impact evaluation.

For further information on this analysis or to schedule an interview, please contact Mariana Fernandez, Corporate Communications at mariana.fernandez@frost.com or (210) 348.1012.

Forward-looking medical imaging companies will aim to tap the abundant growth opportunities in:

  • Evidence-based study ordering, which can help tie imaging activity to specific patient needs by enabling more efficient models.
  • Advanced imaging techniques and personalized image acquisition protocols, which strengthen the capabilities of imaging for definitive diagnosis and prognosis.
  • Adaptive, anatomical, and applied machine intelligence.
  • Precision reporting with informed and correlated study interpretation.
  • Quantitative imaging and radiomics. Radiomics, in combination with genomics, can result in the highly transformative technology of radiogenomics.
  • Image-based, 3D-printed implants and anatomical guides. 3D printing can greatly aid precision medicine by generating patient-tailored, made-to-fit devices, including surgical cutting guides, biocompatible implants, and deformable models for surgical training.
  • Real-time, image-guided interventions. High-precision techniques such as interventional oncology, external beam radiotherapy, and focused ultrasound are raising the profile of interventional oncology.
  • Precise oncologic radiation dose therapy. A new generation of treatment planning and dose measurement applications is driving radiotherapy toward more precise and adaptive radiation therapy.
  • Molecular imaging of theranostic radiotracers.
  • Imaging study value, quality, and outcomes analytics. Operational and financial analytics are evolving beyond tracking basic key performance indicators (KPIs) related to imaging to covering complete business intelligence platforms.

"While most major imaging companies are keen to make the most of the opportunities in precision imaging, they are at various levels of adoption. For instance, Siemens Healthineers has fully embraced the precision trend since it offers multi-pronged value through its solutions portfolio," noted Saha. "At Philips Healthcare, a few precision hot spots have been forming, notably in image-guided therapies and oncology informatics. GE Healthcare, on the other hand, is looking to combine the precision paradigm with Applied Intelligence."

Growth Opportunities in Precision Medical Imaging, Forecast to 2022 is part of Frost & Sullivan’s global Transformational Health Growth Partnership Service program.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Growth Opportunities in Precision Medical Imaging, Forecast to 2022
MDC8-50

Contact:

Mariana Fernandez
Corporate Communications
T: +1 210 348 10 12
T: +54 11 4778 3540
E: Mariana.Fernandez@frost.com
http://ww2.frost.com


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks


More Info:

Investorideas.com Newswire

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp